Epigenome screening highlights that JMJD6 confers an epigenetic vulnerability and mediates sunitinib sensitivity in renal cell carcinoma
Open Access
- 14 February 2021
- journal article
- research article
- Published by Wiley in Clinical and Translational Medicine
- Vol. 11 (2), e328
- https://doi.org/10.1002/ctm2.328
Abstract
Aberrant epigenetic reprogramming represents a hallmark of renal cell carcinoma (RCC) tumorigenesis and progression. Whether there existed other epigenetic vulnerabilities that could serve as therapeutic targets remained unclear and promising. Here, we combined the clustered regularly interspaced short palindromic repeats functional screening results and multiple RCC datasets to identify JMJD6 as the potent target in RCC. JMJD6 expression correlated with poor survival outcomes of RCC patients and promoted RCC progression in vitro and in vivo. Mechanistically, aberrant p300 led to high JMJD6 expression, which activated a series of oncogenic crosstalk. Particularly, high‐throughput sequencing data revealed that JMJD6 could assemble super‐enhancers to drive a list of identity genes in kidney cancer, including VEGFA, β‐catenin, and SRC. Moreover, this JMJD6‐mediated oncogenic effect could be suppressed by a novel JMJD6 inhibitor (SKLB325), which was further demonstrated in RCC cells, patient‐derived organoid models, and in vivo. Given the probable overlapped crosstalk between JMJD6 signature and tyrosine kinase inhibitors downstream targets, targeting JMJD6 sensitized RCC to sunitinib and was synergistic when they were combined together. Collectively, this study indicated that targeting JMJD6 was an effective approach to treat RCC patients.Keywords
Funding Information
- National Natural Science Foundation of China (81972405)
This publication has 52 references indexed in Scilit:
- Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4ACS Chemical Biology, 2015
- Genome-wide CRISPR Screen in a Mouse Model of Tumor Growth and MetastasisCell, 2015
- The roles of chromatin-remodelers and epigenetic modifiers in kidney cancerCancer Genetics, 2015
- Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancerNature, 2014
- JMJD6 Promotes Colon Carcinogenesis through Negative Regulation of p53 by HydroxylationPLoS Biology, 2014
- JMJD6 Regulates ERα Methylation on ArgininePLOS ONE, 2014
- Genome-Scale CRISPR-Cas9 Knockout Screening in Human CellsScience, 2014
- Brd4 and JMJD6-Associated Anti-Pause Enhancers in Regulation of Transcriptional Pause ReleaseCell, 2013
- Loss-of-function genetic screens as a tool to improve the diagnosis and treatment of cancerOncogene, 2009
- JMJD6 Is a Histone Arginine DemethylaseScience, 2007